These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36297661)

  • 1. Population Pharmacokinetic/Pharmacodynamic Modelling of Daptomycin for Schedule Optimization in Patients with Renal Impairment.
    García-Martínez T; Bellés-Medall MD; García-Cremades M; Ferrando-Piqueres R; Mangas-Sanjuán V; Merino-Sanjuan M
    Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of daptomycin in critically ill patients.
    Soraluce A; Asín-Prieto E; Rodríguez-Gascón A; Barrasa H; Maynar J; Carcelero E; Soy D; Isla A
    Int J Antimicrob Agents; 2018 Aug; 52(2):158-165. PubMed ID: 29572042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis.
    Patel N; Cardone K; Grabe DW; Meola S; Hoy C; Manley H; Drusano GL; Lodise TP
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1677-83. PubMed ID: 21282429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy.
    Xu X; Khadzhynov D; Peters H; Chaves RL; Hamed K; Levi M; Corti N
    Br J Clin Pharmacol; 2017 Mar; 83(3):498-509. PubMed ID: 27628437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureus.
    Soon RL; Turner SJ; Forrest A; Tsuji BT; Brown J
    Int J Antimicrob Agents; 2013 Jul; 42(1):53-8. PubMed ID: 23684388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PK/PD modeling of daptomycin against MRSA and MRSE and Monte Carlo simulation for bacteremia treatment.
    Menezes B; Alves I; Staudt K; Beltrame B; Michelin L; de Araújo BV; Tasso L
    Braz J Microbiol; 2021 Dec; 52(4):1967-1979. PubMed ID: 34337679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of daptomycin in critically ill patients receiving extracorporeal membrane oxygenation.
    Zhang LC; Li QY; Zhang YQ; Shan TC; Li Y; Li YH; Han H; Qin WD; Guo HP; Zhao W; Tang BH; Chen XM
    J Antimicrob Chemother; 2024 Jul; 79(7):1697-1705. PubMed ID: 38814793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic/Pharmacodynamic Analysis of Daptomycin Against Staphylococcus aureus and Enterococcus faecium in Pediatric Patients by Monte Carlo Simulation.
    Wei XC; Zhao MF; Li X; Xiao X
    J Clin Pharmacol; 2020 Jun; 60(6):768-774. PubMed ID: 32080861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetic and pharmacodynamic analysis of daptomycin and the necessity of high-dose regimen in Japanese adult patients.
    Urakami T; Hamada Y; Oka Y; Okinaka T; Yamakuchi H; Magarifuchi H; Aoki Y
    J Infect Chemother; 2019 Jun; 25(6):437-443. PubMed ID: 30782427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of intravenous daptomycin in critically ill patients: implications for selection of dosage regimens.
    Wu J; Zheng X; Zhang L; Wang J; Lv Y; Xi Y; Wu D
    Front Pharmacol; 2024; 15():1378872. PubMed ID: 38756382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics/pharmacodynamics analysis and establishment of optimal dosing regimens using unbound cefmetazole concentration for patients infected with Extended-Spectrum β-lactamase producing Enterobacterales (ESBL-E).
    Namiki T; Yokoyama Y; Hashi H; Oda R; Jibiki A; Kawazoe H; Matsumoto K; Suzuki S; Nakamura T
    Pharmacotherapy; 2024 Feb; 44(2):149-162. PubMed ID: 37984818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies.
    Cojutti PG; Candoni A; Ramos-Martin V; Lazzarotto D; Zannier ME; Fanin R; Hope W; Pea F
    J Antimicrob Chemother; 2017 Aug; 72(8):2342-2350. PubMed ID: 28575511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic Model for Unbound Concentrations of Daptomycin in Patients with MRSA Including Patients Undergoing Hemodialysis.
    Takahashi S; Tsuji Y; Holford N; Ogami C; Kasai H; Kawasuji H; To H; Yamamoto Y
    Eur J Drug Metab Pharmacokinet; 2023 Mar; 48(2):201-211. PubMed ID: 36862367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis.
    Xu H; Zhou W; Zhou D; Li J; Al-Huniti N
    J Clin Pharmacol; 2017 Mar; 57(3):336-344. PubMed ID: 27530649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis.
    Fernández de Gatta Mdel M; Santos Buelga D; Sánchez Navarro A; Dominguez-Gil A; García MJ
    Clin Pharmacokinet; 2009; 48(4):273-80. PubMed ID: 19492872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed dose daptomycin: An opportunity for pharmacokinetic/pharmacodynamic optimization in Staphylococcus aureus infections.
    Olney KB; Pai MP; Thomas JK; Burgess DR; Olney WJ; Bruning RA; Griffith KA; Casaus DV; Crance E; Porterfield JZ; Burgess DS
    Pharmacotherapy; 2024 Aug; 44(8):615-622. PubMed ID: 39078247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis.
    Chen CY; Xie M; Gong J; Yu N; Wei R; Lei LL; Zhao SM; Li RM; Dong X; Zhang XL; Zhou Y; Li SL; Cui YM
    Front Pharmacol; 2023; 14():1132367. PubMed ID: 37188268
    [No Abstract]   [Full Text] [Related]  

  • 18. Simplified daptomycin dosing regimen for adult patients with methicillin-resistant Staphylococcus aureus infections based on population pharmacokinetic analysis.
    Yamada T; Soda M; Nishida R; Miyake N; Maeshiro Y; Oida Y; Yamashita Y; Egashira N; Shimono N; Kitaichi K; Ieiri I
    Drug Metab Pharmacokinet; 2022 Jun; 44():100444. PubMed ID: 35462110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment.
    Grégoire N; Marchand S; Ferrandière M; Lasocki S; Seguin P; Vourc'h M; Barbaz M; Gaillard T; Launey Y; Asehnoune K; Couet W; Mimoz O
    J Antimicrob Chemother; 2019 Jan; 74(1):117-125. PubMed ID: 30295740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo pharmacodynamic activity of daptomycin.
    Safdar N; Andes D; Craig WA
    Antimicrob Agents Chemother; 2004 Jan; 48(1):63-8. PubMed ID: 14693519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.